Edwards Lifesciences Q2 FY26: sales up 13.6%, adjusted EPS $0.78
Edwards beat its own sales guidance and edged past the $0.7627 adjusted EPS consensus, so the operating story is strong even though GAAP EPS fell to $0.42 from $0.56. The gap between $0.42 and $0.78 is mostly a $188.2 million tax charge, not a change in the business. Read revenue growth and adjusted EPS as the operating signal here, and treat GAAP net income as a one-off tax story.
1 · Expected vs. Actual
Free preview belowAdjusted EPS of $0.78 came in ahead of the $0.7627 consensus and above $0.67 a year ago. GAAP EPS fell to $0.42 from $0.56, mostly because of a $188.2 million valuation allowance tied to California's new limit on R&D tax credits ($0.33 per share) plus a $40.0 million impairment ($0.05). The effective tax rate jumped to 53.6% from 16.1%.
Revenue of $1.741 billion rose 13.6% from $1.532 billion a year ago, or 12.5% in constant currency. That cleared the $1.70 billion midpoint guided a quarter earlier. TAVR supplied $1.2583 billion of the total and TMTT $198.6 million.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-09-17
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.